Vol. 49 | No. 2 | July-December 2021 Back

Open Access

Prevalence, Awareness, and Treatment Profile of Adult Filipino Hypertensive Individuals: Philippine Heart Association–Council on Hypertension Report on Survey of Hypertension (PRESYON-4)

Jorge A. Sison, Roberta Maria Cawed-Mende, Raymond V. Oliva
Dec 2021 DOI 10.69944/pjc.e0ed50316d

Abstract

BACKGROUND: Hypertension is one of the leading causes of cardiovascular morbidity and  mortality in the Philippines. The prevalence rate of hypertension has been increasing, and this  was associated with increasing comorbidities and poor control rates. The Philippine Heart  Association–Council on Hypertension has been conducting the PRESYON studies since 1992 to  determine the present hypertension rates. This updated PRESYON-4 aimed to know the latest  numbers of hypertension cases in the country and to determine the awareness, treatment profile,  and control rates of individuals afflicted with hypertension. 

METHODS: PRESYON-4 is a randomized, prospective, multistage, stratified, nationwide survey  conducted last January to April 2021. It included 3,437 participants; 2,796 subjects were adults  aged 19 years or older, and the rest of the participants were 12 to 18 years old. The prevalence  of hypertension was analyzed from the survey. Anthropometric measurements, risk factors, and  comorbidity assessment were also determined. 

RESULTS: The prevalence rate of hypertension in the latest survey is 37%, with more than half  of the respondents aware of their disease. Utilizing the classification of the European guidelines  for hypertension, 34% had grade 1 hypertension, with 26% of participants having isolated  systolic hypertension. Individuals older than 50 years are aware of their elevated blood pressure  (BP), but more females are aware of their disease compared with men. Current smoking and  obesity are high in the hypertensive population, whereas diabetes mellitus and angina are the  more common comorbidities. Most subjects utilize the oscillometric arm BP apparatus to monitor  their BP. Angiotensin receptor blockers are the most used antihypertensive medication with a  high compliance rate. However, there is poor control among treated patients with hypertension,  as the control rate is only 39%. The prescription of a single drug is still prevalent among Filipino  hypertensive individuals. 

CONCLUSION: The point prevalence of hypertension in the country is at 37% based on the  analysis. The need to manage risk factors such as obesity and smoking should be part of  management. A multisectoral approach in the management of hypertension should be part of the  strategy to lower hypertension in the country. 

KEYWORDS: hypertension, prevalence, awareness, compliance, BP control

References
  1. Bina JJ, Noublap JJ. The rising burden of non communicable diseases in sub-Saharan Africa. Lancet Glob Health 2019;7(10e):1295–1296.
  2. Masilela C, Pearce B, Ongole JJ, Adeniyi OV, Mongi Benjeddou M. Cross-sectional study of prevalence and determinants of uncontrolled hypertension among South African adult residents of Mkhondo municipality. BMC Public Health 2022;20:1069.
  3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217–223.
  4. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;376:391–603.
  5. Dahlof B. Prevention of stroke in patients with hypertension. Am J Cardiol 2007;100:17J–24J.
  6. Gao Y, Chen G, Tian H, et al. Prevalence of hypertension in China: A cross-sectional study. PLoS One 2013;8(6):e65938.
  7. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441–450.
  8. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959–968.
  9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA. Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2018;138:e484–e594.
  10. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2015 hypertension guidelines with cardiovascular events and deaths in US adults: An analysis of nation data. JAMA Cardiol 2017;2:775–781.
  11. Wang Zm Chen Z, Zhang L, et al. Status of hypertension in China. Circulation 2018;137:2344–2356.
  12. 2013 8th National Nutrition Survey of the Food and Nutrition Research Institute, Department of Science and Technology. https://drive.google.com/file/d/1D6tbN4poyg3 WkAFRBboO3L16o2bd__W_/view
  13. Philippine Heart Association-Council on Hypertension. Philippine Heart Association—Council of Hypertension Report on Survey of Hypertension (PRESYON 3): A profile on prevalence of hypertension, awareness and treatment profile. Phil J Cardiol 2013;41(1):43–48.
  14. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines in the management of arterial hypertension. Eur Heart J 2018;00:1–98.
  15. Mills K, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020;16(4):223–237. 16. Ostroff J, Wolff M. An overview of generic angiotensin receptor blockers. US Pharm 2016;41(6)(generic suppl):44–50.
  16. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352–358.
  17. Chalmers J, Mourad JJ, De Champvallins M, Mancia G. Benefits of indapamide-based treatment on mortality: A systematic review and meta-analysis. J Hypertens 2009;37:p357.
  18. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol and doxazosin to determine the treatment for drug-resistant hypertension (PATHWAY-2): A randomized, double-blind, crossover trial. Lancet 2015;386:2069.
  19. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 2001;15:79–87.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.